Anti-angiogenic Therapy in Cancer: Downsides and New Pivots for Precision Medicine
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Anti-angiogenic Therapy in Cancer: Downsides and New Pivots for Precision Medicine
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 07, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2017-01-06
DOI
10.3389/fphar.2016.00519
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting hypoxia to overcome radiation resistance in head & neck cancers: real challenge or clinical fairytale?
- (2016) René Baumann et al. Expert Review of Anticancer Therapy
- Tumor angiogenesis—characteristics of tumor endothelial cells
- (2016) Kyoko Hida et al. International Journal of Clinical Oncology
- A novel family of fluorescent hypoxia sensors reveal strong heterogeneity in tumor hypoxia at the cellular level
- (2015) R. Erapaneedi et al. EMBO JOURNAL
- Identification of imaging biomarkers for the assessment of tumour response to different treatments in a preclinical glioma model
- (2015) A. Lo Dico et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Vesicular trafficking mechanisms in endothelial cells as modulators of the tumor vasculature and targets of antiangiogenic therapies
- (2015) Hannelore Maes et al. FEBS Journal
- A common polymorphism in the 5′ UTR of ERCC5 creates an upstream ORF that confers resistance to platinum-based chemotherapy
- (2015) Joanna Somers et al. GENES & DEVELOPMENT
- Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
- (2015) Calin Cainap et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
- (2015) William M. Sikov et al. JOURNAL OF CLINICAL ONCOLOGY
- Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases
- (2015) Han-Sin Jeong et al. JNCI-Journal of the National Cancer Institute
- Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial
- (2015) Helena M Earl et al. LANCET ONCOLOGY
- Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
- (2015) Jordi Bruix et al. LANCET ONCOLOGY
- Monitoring vascular normalization induced by antiangiogenic treatment with 18F-fluoromisonidazole-PET
- (2015) Elena Hernández-Agudo et al. Molecular Oncology
- Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer
- (2015) Rebecca S. Heist et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Optimizing Hypoxia Detection and Treatment Strategies
- (2015) Cameron J. Koch et al. SEMINARS IN NUCLEAR MEDICINE
- The effect of triamcinolone acetonide on laser-induced choroidal neovascularization in mice using a hypoxia visualization bio-imaging probe
- (2015) Shinsuke Takata et al. Scientific Reports
- Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases
- (2015) Han-Sin Jeong et al. JNCI-Journal of the National Cancer Institute
- An in vitro retinoblastoma human triple culture model of angiogenesis: A modulatory effect of TGF-β
- (2014) Gabriella Lupo et al. CANCER LETTERS
- Antiangiogenesis Therapy for Breast Cancer: An Update and Perspectives from Clinical Trials
- (2014) Elham Fakhrejahani et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
- (2014) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
- (2014) Marcia S Brose et al. LANCET
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
- (2014) Hansjochen Wilke et al. LANCET ONCOLOGY
- A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
- (2014) Mark R. Gilbert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Bevacizumab in Advanced Cervical Cancer
- (2014) Krishnansu S. Tewari et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multi-Targeted Antiangiogenic Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer: Meta-Analyses of 20 Randomized Controlled Trials and Subgroup Analyses
- (2014) Wenhua Liang et al. PLoS One
- A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer
- (2013) T. Powles et al. ANNALS OF ONCOLOGY
- Endothelial PKCα-MAPK/ERK-phospholipase A2 pathway activation as a response of glioma in a triple culture model. A new role for pericytes?
- (2013) Carmelina Daniela Anfuso et al. BIOCHIMIE
- VEGF receptor-1 involvement in pericyte loss induced byEscherichia coliin anin vitromodel of blood brain barrier
- (2013) Mario Salmeri et al. CELLULAR MICROBIOLOGY
- The Effect of VEGF-Targeted Therapy on Biomarker Expression in Sequential Tissue from Patients with Metastatic Clear Cell Renal Cancer
- (2013) K. Sharpe et al. CLINICAL CANCER RESEARCH
- Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
- (2013) Rakesh K. Jain JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer
- (2013) M. Dror Michaelson et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma
- (2013) Thomas E. Hutson et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Trial of Temsirolimus and Bevacizumab Versus Interferon Alfa and Bevacizumab in Metastatic Renal Cell Carcinoma: INTORACT Trial
- (2013) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
- (2013) Charles S Fuchs et al. LANCET
- Colorectal Cancer Cells Refractory to Anti-VEGF Treatment Are Vulnerable to Glycolytic Blockade due to Persistent Impairment of Mitochondria
- (2013) J. Xu et al. MOLECULAR CANCER THERAPEUTICS
- Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy
- (2013) Kyrre E Emblem et al. NATURE MEDICINE
- An interleukin-17–mediated paracrine network promotes tumor resistance to anti-angiogenic therapy
- (2013) Alicia S Chung et al. NATURE MEDICINE
- The role of tumour–stromal interactions in modifying drug response: challenges and opportunities
- (2013) Douglas W. McMillin et al. NATURE REVIEWS DRUG DISCOVERY
- The irradiated tumor microenvironment: role of tumor-associated macrophages in vascular recovery
- (2013) Jeffery S. Russell et al. Frontiers in Physiology
- Heterogeneity of Tumor Endothelial Cells
- (2012) Noritaka Ohga et al. AMERICAN JOURNAL OF PATHOLOGY
- Pericyte Depletion Results in Hypoxia-Associated Epithelial-to-Mesenchymal Transition and Metastasis Mediated by Met Signaling Pathway
- (2012) Vesselina G. Cooke et al. CANCER CELL
- VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex
- (2012) Kan V. Lu et al. CANCER CELL
- Anti-VEGF/VEGFR Therapy for Cancer: Reassessing the Target
- (2012) B. Sitohy et al. CANCER RESEARCH
- Heterogeneity of the tumor vasculature: the need for new tumor blood vessel type-specific targets
- (2012) Janice A. Nagy et al. CLINICAL & EXPERIMENTAL METASTASIS
- Targeting Hypoxia, HIF-1, and Tumor Glucose Metabolism to Improve Radiotherapy Efficacy
- (2012) T. W. H. Meijer et al. CLINICAL CANCER RESEARCH
- Carbonic Anhydrase IX Promotes Tumor Growth and Necrosis In Vivo and Inhibition Enhances Anti-VEGF Therapy
- (2012) A. McIntyre et al. CLINICAL CANCER RESEARCH
- Bevacizumab in Stage II-III Colon Cancer: 5-Year Update of the National Surgical Adjuvant Breast and Bowel Project C-08 Trial
- (2012) Carmen J. Allegra et al. JOURNAL OF CLINICAL ONCOLOGY
- Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors
- (2012) Alicia S Chung et al. JOURNAL OF PATHOLOGY
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
- (2012) Aimery de Gramont et al. LANCET ONCOLOGY
- Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
- (2012) Jaafar Bennouna et al. LANCET ONCOLOGY
- An oxygen-regulated switch in the protein synthesis machinery
- (2012) James Uniacke et al. NATURE
- Phase II Trials of Imatinib Mesylate and Docetaxel in Patients with Metastatic Non-small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma
- (2011) Anne S. Tsao et al. Journal of Thoracic Oncology
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
- (2011) Robert A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Normalization of the Vasculature for Treatment of Cancer and Other Diseases
- (2011) Shom Goel et al. PHYSIOLOGICAL REVIEWS
- Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma
- (2011) Olivier Keunen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Isolated tumor endothelial cells maintain specific character during long-term culture
- (2010) Kohei Matsuda et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Angiogenic factor signaling regulates centrosome duplication in endothelial cells of developing blood vessels
- (2010) S. M. Taylor et al. BLOOD
- Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma
- (2010) Manuela Schmidinger et al. CANCER TREATMENT REVIEWS
- Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
- (2010) Hedy Lee Kindler et al. JOURNAL OF CLINICAL ONCOLOGY
- Advances in Combination of Antiangiogenic Agents Targeting VEGF-binding and Conventional Chemotherapy and Radiation for Cancer Treatment
- (2010) Li-Song Teng et al. Journal of the Chinese Medical Association
- Glioblastoma stem-like cells give rise to tumour endothelium
- (2010) Rong Wang et al. NATURE
- Stromal PDGFRβ Expression in Prostate Tumors and Non-Malignant Prostate Tissue Predicts Prostate Cancer Survival
- (2010) Christina Hägglöf et al. PLoS One
- Prognostic Significance of Stromal Platelet-Derived Growth Factor β-Receptor Expression in Human Breast Cancer
- (2009) Janna Paulsson et al. AMERICAN JOURNAL OF PATHOLOGY
- Treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of radiation therapy
- (2009) H Harada et al. BRITISH JOURNAL OF CANCER
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
- (2009) John M.L. Ebos et al. CANCER CELL
- Regulation of XIAP Translation and Induction by MDM2 following Irradiation
- (2009) Lubing Gu et al. CANCER CELL
- Intussusceptive microvascular growth in human glioma
- (2009) Beatrice Nico et al. CLINICAL AND EXPERIMENTAL MEDICINE
- Biomechanical regulation of blood vessel growth during tissue vascularization
- (2009) Witold W Kilarski et al. NATURE MEDICINE
- Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
- (2009) G L Semenza ONCOGENE
- Glycolytic metabolism and tumour response to fractionated irradiation
- (2009) Ulrike G.A. Sattler et al. RADIOTHERAPY AND ONCOLOGY
- Angiogenesis, hypoxia and VEGF expression during tumour growth in a human xenograft tumour model
- (2008) E.M. Hendriksen et al. MICROVASCULAR RESEARCH
- Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1
- (2008) M. Y. Koh et al. MOLECULAR CANCER THERAPEUTICS
- A role for VEGF as a negative regulator of pericyte function and vessel maturation
- (2008) Joshua I. Greenberg et al. NATURE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started